SEC Tracker
Get the app

Fibrogen KYNB

Fibrogen FY 2021: revenue $235.3M, up 33%; diluted EPS −$3.14

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers Fibrogen reported for the year ended Dec 31, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$235.3M+33% from $176.3M in FY 202010-K/A income statement, on EDGAR
  2. Net income−$290.0MAgainst −$189.3M in FY 202010-K/A income statement, on EDGAR
  3. Diluted EPS−$3.14Against −$2.11 in FY 202010-K income statement, on EDGAR
  4. Cash and cash equivalents$171.2M−75% from $678.4M in FY 2020Cash and equivalents only; the company page adds short-term investments.10-K/A balance sheet, on EDGAR
  5. Cash from operations−$82.2M−201% from $81.6M in FY 202010-K/A cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Fibrogen files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025
  2. Imunon IMNN public float $21M, Jun 30, 2025
  3. Lunai Bioworks LNAI public float $21M, Dec 31, 2025
  4. Dare Bioscience DARE public float $21M, Jun 30, 2025
  5. Aptose Biosciences APTOF public float $22M, Jun 28, 2025